Evidence map›Paper›PMID 29263066›Full record

ArticleAntimicrobial agents and chemotherapy2018

Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes.

Wan Ahmad Kamil Wan Nur Ismah, Yuiko Takebayashi, Jacqueline Findlay, Kate J Heesom, Juan-Carlos Jiménez-Castellanos, Jay Zhang, Lee Graham, Karen Bowker, O Martin Williams, Alasdair P MacGowan and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Mutations in the efflux regulator geneMicrobiology (Reading, England) · 2024
    Article
  4. Article
  5. One health transmission of fluoroquinolone-resistantOne health (Amsterdam, Netherlands) · 2023
    Article
  6. Evidence that faecal carriage of resistantOne health (Amsterdam, Netherlands) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Mutation ofAntimicrobial agents and chemotherapy · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Wan Ahmad Kamil Wan Nur IsmahSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Yuiko TakebayashiSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Jacqueline FindlaySchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Kate J HeesomBristol Proteomics Facility, University of Bristol, Bristol, United Kingdom.
Juan-Carlos Jiménez-CastellanosSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Jay ZhangSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Lee GrahamDepartment of Infection Sciences, Severn Infection Partnership, Southmead Hospital, Bristol, United Kingdom.
Karen BowkerDepartment of Infection Sciences, Severn Infection Partnership, Southmead Hospital, Bristol, United Kingdom.
O Martin WilliamsDepartment of Infection Sciences, Severn Infection Partnership, Southmead Hospital, Bristol, United Kingdom.
Alasdair P MacGowanSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Matthew B AvisonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom matthewb.avison@bris.ac.uk.
University of Bristol · GBSouthmead Hospital · GBUniversiti Putra Malaysia · MY

Funding

Biotechnology and Biological Sciences Research Council BB/L024209/1Medical Research Council MR/N013646/1
6 · The paper itself

Abstract

Fluoroquinolone resistance in Gram-negative bacteria is multifactorial, involving target site mutations, reductions in fluoroquinolone entry due to reduced porin production, increased fluoroquinolone efflux, enzymes that modify fluoroquinolones, and Qnr, a DNA mimic that protects the drug target from fluoroquinolone binding. Here we report a comprehensive analysis, using transformation and

Indexed as

Anti-Bacterial AgentsChromatography, LiquidFluoroquinolonesGenotypeKlebsiella pneumoniaeMicrobial Sensitivity TestsTandem Mass SpectrometryWhole Genome SequencingAnti-Bacterial AgentsFluoroquinolonesantibiotic resistanceKlebsiella pneumoniaesusceptibility testing

Identifiers

PMID29263066
PMCPMC5826109
OpenAlexW2950741596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.